Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25404727 | 1.00 | DGAT1 (0.34) | DGAT1CA1CA2CA7LMNA | |
| SCHEMBL17965817 | 0.89 | CA1 (0.39) | DGAT1CA1CA2CA7LMNA | |
| SCHEMBL27659910 | 0.85 | LMNA (0.31) | DGAT1CA1CA2CA7LMNA | |
| SCHEMBL28802149 | 0.78 | CA1 (0.36) | DGAT1CA1CA2CA7LMNA | |
| SCHEMBL27357842 | 0.78 | NOS1 (0.38) | DGAT1CA1CA2CA7LMNA | |
| SCHEMBL27790857 | 0.77 | DGAT1 (0.35) | DGAT1CA1CA2CA7LMNA | |
| SCHEMBL17094539 | 0.75 | LMNA (0.39) | DGAT1CA1CA2CA7LMNA | |
| SCHEMBL17094267 | 0.75 | LMNA (0.39) | DGAT1CA1CA2CA7LMNA | |
| SCHEMBL3183015 | 0.75 | LMNA (0.39) | DGAT1CA1CA2CA7LMNA | |
| SCHEMBL1629957 | 0.75 | DPP4 (0.32) | DGAT1CA1CA2CA7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031927-A1 | Alkyl 2--propionates, nucleoside inhibitors of HCV RNA-polymerase NS5B, methods for preparation and use thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (RU) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031927-A1 | Alkyl 2--propionates, nucleoside inhibitors of HCV RNA-polymerase NS5B, methods for preparation and use thereof | RNGTT, NSUN2, MED1 | DGAT1 329/4885CA1 3871/4885CA2 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.